ArticleDermatology and therapy2025

Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.

Yan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.